We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.75 | 0.99% | 76.55 | 76.27 | 77.00 | 76.49 | 75.43 | 76.47 | 9,026,349 | 01:00:00 |
From May 2022 to May 2024
By Ian Walker
AstraZeneca PLC said Tuesday that it is buying biotechnology company Neogene Therapeutics Inc. for up to $320 million.
The pharmaceutical giant said it will pay an initial sum of $200 million upon the deal closing, which is expected in the first quarter of next year. The rest of the money is dependent upon certain milestones being met.
The deal doesn't impact the company's financial guidance for the current year, the company said.
"This acquisition represents a unique opportunity to bring innovative science and leading experts in T-cell receptor biology and cell therapy manufacturing together with our internal oncology cell therapy team, unlocking new ways to target cancer," said Susan Galbraith, Astra's Executive Vice President, Oncology R&D.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
November 29, 2022 02:38 ET (07:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
